Avadomide hydrochloride is under clinical development by Bristol-Myers Squibb and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase I drugs for Follicular Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Avadomide hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Avadomide hydrochloride overview

CC-122 is under development for the treatment of advanced solid tumors including non-Hodgkin's lymphoma, relapsed/refractory multiple myeloma, chronic lymphocytic leukemia, follicular lymphoma, small lymphocytic lymphoma, diffuse large B cell lymphoma, indolent lymphoma, hepatocellular carcinoma, primary glioblastoma multiforme, metastatic melanoma and gliosarcoma. It is also under development in combination with nivolumab for the treatment of hepatocellular carcinoma who have progressed after or were intolerant to no more than 2 previous systemic therapies for unresectable HCC or are naive to systemic therapy. The drug candidate is administered orally in the form of the capsule. It is a next generation molecular glue CELMoD compound (Cereblon E3 Ligase Modulation Drugs) which acts by targeting CRBN (cereblon). The drug candidate is a non-phthalimide analog of the immunomodulatory drugs such as thalidomide.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Avadomide hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.